Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8306186 | 0.79 | ALDH1A1 (0.35) | ALDH1A1HSD17B10P2RX7KDM4ENPC1 | |
| SCHEMBL23884995 | 0.76 | ALDH1A1 (0.33) | ALDH1A1HSD17B10KDM4ENPC1RAB9A | |
| SCHEMBL21631702 | 0.76 | ALDH1A1 (0.33) | ALDH1A1HSD17B10KDM4ENPC1RAB9A | |
| SCHEMBL18876099 | 0.76 | P2RX7 (0.34) | ALDH1A1HSD17B10P2RX7KDM4ENPC1 | |
| SCHEMBL3185104 | 0.76 | DYRK1A (0.35) | ALDH1A1HSD17B10P2RX7KDM4ENPC1 | |
| SCHEMBL20855206 | 0.76 | ALDH1A1 (0.33) | ALDH1A1HSD17B10KDM4ENPC1RAB9A | |
| SCHEMBL30002369 | 0.76 | P2RX7 (0.36) | ALDH1A1HSD17B10P2RX7KDM4ENPC1 | |
| SCHEMBL19435587 | 0.76 | NQO2 (0.44) | ALDH1A1HSD17B10P2RX7KDM4ENPC1 | |
| SCHEMBL2722669 | 0.75 | ALDH1A1 (0.46) | ALDH1A1HSD17B10KDM4ENPC1RAB9A | |
| SCHEMBL29324220 | 0.73 | ADORA2A (0.33) | ALDH1A1HSD17B10P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116406272-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-114195805-A | DNA-PK selective inhibitor and preparation method and application thereof | 首药控股(北京)股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022017368-A1 | DNA-PK SELECTIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 首药控股(北京)股份有限公司 | 2022-01-27 | — | — | WO | disclosed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| CN-101553490-A | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS INC (US) | 2009-10-07 | — | — | CN | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | ALDH1A1 4730/4885HSD17B10 3055/4885P2RX7 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.